ArticleLeukemia2023
Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression.
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- ANKRD28 interacts with DOCK180 to activate Rac1-STAT3-Myc signaling and sustain stemness of CD34Molecular and cellular biochemistry · 2026Article
- Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.HemaSphere · 2026Article
- MDSC subpopulation dynamics predict disease evolution: a multidimensional biomarker framework for risk assessment in MDS.Clinical and experimental medicine · 2026Article
- C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia.Molecular biology reports · 2025Review
- GMP-like and MLP-like Subpopulations of Hematopoietic Stem and Progenitor Cells Harboring MutatedInternational journal of molecular sciences · 2025Article
- Unveiling the potential of CLL-1: a promising target for AML therapy.Biomarker research · 2025Review
- CD56 on immune and tumor cells: what is known and beyond?Clinical and experimental immunology · 2025Review
- Analysis of the Correlation Between MDS Inflammatory Indicators and Clinical Characteristics: A Comprehensive Analysis.Mediators of inflammation · 2025Article
- Article
- Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.Leukemia · 2024Article
- Article
- Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence.Frontiers in oncology · 2024Review
- Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.Blood advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelodysplastic syndromes (MDS) comprise hematological disorders that originate from the neoplastic transformation of hematopoietic stem cells (HSCs). However, discrimination between HSCs and their neoplastic counterparts in MDS-derived bone marrows (MDS-BMs) remains challenging. We hypothesized that in MDS patients immature CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.